Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Basilea sales and marketing update

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Business: Infectious Basilea launched Zevtera ceftobiprole in Germany to treat bacterial lung infections. The product is a broad-spectrum cephalosporin antibiotic …

    Published on 12/15/2014
  • Merck KGaA sales and marketing update

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Other Mercks EMD Serono subsidiary launched smartphone application, Check My Meds, in the U.S. to enable patients to verify that their medication is not counterfeit …

    Published on 12/15/2014
  • PTC sales and marketing update

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Business: Musculoskeletal PTC launched Translarna ataluren in Germany to treat nonsense mutation Duchenne muscular dystrophy (DMD). The product is a small …

    Published on 12/15/2014
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Autoimmune Sanofis Genzyme Corp. launched Lemtrada alemtuzumab in the U.S. to treat relapsing forms of multiple sclerosis (MS). The wholesale acquisition cost (…

    Published on 12/15/2014
  • Veracyte sales and marketing update

    Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. Business: Diagnostic Veracyte said Blue Shield of California issued positive coverage decisions for Afirma Gene Expression Classifier. Afirma is a preoperative …

    Published on 12/15/2014
  • Zydus sales and marketing update

    Zydus Cadila Group (NSE:CADILAHC; BSE:532321), Ahmedabad, India Business: Autoimmune, Biosimilars Zydus launched Exemptia, a biosimilar of adalimumab, in India to treat autoimmune disorders including rheumatoid …

    Published on 12/15/2014
  • 23andMe sales and marketing update

    23andMe Inc., Mountain View, Calif. Business: Diagnostic 23andMe launched its Personal Genome Service (PGS) in the U.K. at a price of L125 ($195.15). Last year, the company halted sales of the service in the U.S. for …

    Published on 12/8/2014
  • Adaptive Biotechnologies sales and marketing update

    Adaptive Biotechnologies Corp., Seattle, Wash. Business: Diagnostic Adaptive launched immunoSEQ kit in the U.S. for research only to measure T cell receptor beta (TCRB) in immune-mediated diseases. The company plans to…

    Published on 12/8/2014
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisais Eisai Laboratorios Ltda. subsidiary launched Halaven eribulin in Brazil to treat locally advanced or metastatic breast cancer. Halaven is a synthetic …

    Published on 12/8/2014
  • Epirus, Ranbaxy sales and marketing update

    Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Gurgaon, India Business: Biosimilars, Autoimmune The companies launched Infimab infliximab, a generic of …

    Published on 12/8/2014
  • Exact Sciences, CMS sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Centers for Medicare & Medicaid Services, Baltimore, Md. Business: Diagnostic CMS will reimburse patients using Exacts Cologuard colon cancer diagnostic at $502 per test…

    Published on 12/8/2014
  • NeoGenomics sales and marketing update

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Business: Genomics NeoGenomics launched new tests to detect mutations in the Brutons tyrosine kinase (BtK) and phospholipase C gamma 2 (phosphatidylinositol-specific; …

    Published on 12/8/2014
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cancer, Neurology, Generics Teva launched a liquid formulation of Treanda bendamustine injection in the U.S. to treat chronic lymphocytic …

    Published on 12/8/2014
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Diagnostic Biocept launched its OncoCEE-LU blood-based biomarker test for non-small cell lung cancer (NSCLC). The test will be performed at Biocepts CLIA-…

    Published on 11/24/2014
  • Cubist, Omnicare sales and marketing update

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Omnicare Inc. (NYSE:OCR), Cincinnati, Ohio Business: Infectious Omnicares Advanced Care Scripts (ACS) division will provide an integrated pharmacy solution for…

    Published on 11/24/2014
  • Dr. Reddys Laboratories Ltd. sales and marketing update

    Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Business: Transplant Dr. Reddys launched sirolimus tablets for the prophylaxis of organ rejection in patients older than 13 years who have had renal transplants.…

    Published on 11/24/2014
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Neurology Eisai launched Fycompa perampanel in Australia to treat partial-onset seizures with or without secondarily generalized seizures in epileptics ages 12 years …

    Published on 11/24/2014
  • Genomica S.A.U., Scienion sales and marketing update

    Genomica S.A.U., Madrid, Spain Scienion AG, Berlin, Germany Business: Infectious The companies launched Clart STIs A&Beta, a detection kit for identifying and differentiating 18 different microorganisms that cause …

    Published on 11/24/2014
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic, Drug delivery Novo Nordisk launched NovoFine Plus in the U.S. to deliver insulin and some glucagon-like peptide-1 (GLP-1) receptor …

    Published on 11/24/2014
  • Octapharma sales and marketing update

    Octapharma AG, Lachen Switzerland Business: Hematology Octapharmas Octapharma USA subsidiary launched Octagam 10% human IV Ig in the U.S. for adults with chronic immune thrombocytopenic purpura (ITP). The packaging size…

    Published on 11/24/2014
  • Salix sales and marketing update

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Business: Inflammation Salix launched Ruconest conestat alfa in the U.S. to treat acute angioedema attacks in patients with hereditary angioedema (HAE). The …

    Published on 11/24/2014
  • AOP Orphan sales and marketing update

    AOP Orphan Pharmaceuticals AG, Vienna, Austria Business: Hematology AOP Orphan launched Thromboreductin anagrelide in Russia to treat essential thrombocythemia. The product comes in 0.5 mg capsules.

    Published on 11/17/2014
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary Boehringer launched Ofev nintedanib in the U.S. to treat idiopathic pulmonary fibrosis (IPF). Ofev has Orphan Drug and breakthrough therapy status in the…

    Published on 11/17/2014
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Lilly launched Trulicity dulaglutide in the U.S. to help improve glycemic control in adults with Type 2 diabetes. The 0.75 and 1.5 mg …

    Published on 11/17/2014
  • Fluidigm sales and marketing update

    Fluidigm Corp. (NASDAQ:FLDM), South San Francisco, Calif. Business: Microfluidics Fluidigm launched a new application for its C1 single-cell auto prep system called single-cell whole exome sequencing workflow. The new …

    Published on 11/17/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993